CJC-1295 (Growth Hormone Releasing Hormone Analog) – with DAC

Product Overview

CJC-1295 is a highly advanced, synthetic analog of Growth Hormone Releasing Hormone (GHRH) consisting of the first 29 amino acids of native GHRH. What distinguishes this peptide is the addition of a sophisticated Drug Affinity Complex (DAC). This specific modification allows the compound to form an irreversible, covalent bond with serum albumin immediately after administration. This bio-engineering breakthrough protects the peptide from rapid enzymatic degradation, transforming it into a long-acting compound ideal for studying sustained growth hormone (GH) and Insulin-like Growth Factor-1 (IGF-1) elevation.

Technical Specifications

• Molecular Formula: C152H252N44O42

• Molecular Weight: 3367.89 g/mol

• CAS Number: 863288-34-0

• Sequence Profile: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Maleimidopropionyl-Lysine)

Mechanism of Action

CJC-1295 with DAC achieves prolonged hormonal signaling through targeted structural modifications and receptor interaction:

• Covalent Albumin Conjugation: The maleimidopropionyl-lysine linker reacts with Cys34 on serum albumin, creating a circulating depot that extends the biological activity window from mere minutes to up to 6–8 days.

• GHRH Receptor Agonism: Binds directly to GHRH receptors in the pituitary gland to stimulate GH release.

• Pulsatile GH Amplification: Rather than replacing natural GH secretion with a flat, unnatural elevation, CJC-1295 with DAC enhances the amplitude of endogenous, physiological GH pulses, preserving essential regulatory feedback mechanisms (e.g., periodic suppression by somatostatin).

• Synergistic Amplification: When utilized alongside a Growth Hormone Secretagogue (such as Ipamorelin or GHRP-6), it activates complementary pituitary pathways, resulting in a synergistic GH release that is typically 2 to 5 times greater than either peptide administered alone.

Primary Research Applications

CJC-1295 with DAC is a premier compound for in vitro and animal model studies investigating:

• Prolonged IGF-1 and GH Elevation Dynamics

• Body Composition Changes (Lipolysis and Lean Muscle Mass Synthesis)

• Synergistic Peptide Stacking (GHRH + GHRP Combinations)

• Sleep Architecture and Nocturnal GH Secretion Optimization

• Age-Related Growth Hormone Decline and Metabolic Syndrome

Storage & Handling

For optimal long-term stability and structural integrity, store lyophilized powder securely at -4°F (-20°C). Reconstituted solutions should be kept refrigerated at 36°F to 46°F (2°C to 8°C) and utilized within 2 to 4 weeks to protect the DAC albumin-binding moiety from degradation. Repeated freeze-thaw cycles must be avoided.

⚠️ Important Disclaimer for Carbon Nova Labs Customers: All information provided is for educational and reference purposes only. CJC-1295 is sold strictly for laboratory research use only. This compound is not approved by the FDA for human consumption, therapeutic use, or clinical application. Ensure compliance with all institutional safety protocols and consult qualified professionals before conducting research.